ALTHE.PA Theraclion (EURONEXT) up 22.75% on heavy volume 27 Jan 2026: model shows upside
ALTHE.PA stock jumped 22.75% to €0.87 on 27 Jan 2026 on high volume of 560,294 shares, well above the 62,263 average. That surge pushed the intraday range to €0.74–€0.93 and put the Mar 2025 year-high of €1.25 back in focus. Traders cited comparative sector screens and renewed interest in Theraclion SA’s echotherapy devices as the likely driver. We review the price move, the balance sheet signals, technicals and what our forecast model implies for short and medium term investors on EURONEXT in Europe.
ALTHE.PA stock: Price action and volume snapshot
Theraclion SA (ALTHE.PA) closed at €0.87, up €0.16 or 22.75%, with volume at 560,294 versus an average of 62,263. The stock opened at €0.77, printed a day low of €0.74 and a day high of €0.93. Short-term momentum shows the 50-day average at €0.62 and the 200-day average at €0.53, highlighting a recent recovery from the 52-week low of €0.14.
ALTHE.PA stock: News drivers and market context
No single major corporate release explained the spike; market participants referenced sector comparison pages that list Theraclion alongside peers on investing platforms. Increased screening attention in the Medical – Devices group likely amplified orders. See comparative listings on Investing.com for context: Investing.com peer comparison 1 and Investing.com benchmark analysis link 2.
ALTHE.PA stock: Financials and valuation metrics
Theraclion reports EPS -0.11 and a trailing PE of -6.64, reflecting losses. Market cap stands at €34,429,136.00 with 47,163,200 shares outstanding. Price/sales is high at 28.17 and price/book is negative around -13.33, signalling limited revenue scale and negative equity per share. The current ratio 2.40 supports short-term liquidity, but operating cash flow per share is -0.11, pointing to continued cash burn.
ALTHE.PA stock: Technicals, support and resistance
Momentum indicators are mixed: RSI 54.45 and CCI 159.47 indicate moderate strength with short-term overbought signals. MACD is neutral. Immediate support sits near €0.62 (50-day MA) and stronger support near €0.53 (200-day MA). Near-term resistance lies at €0.93 then the 52-week high €1.25. The stock’s relative volume of 3.25x suggests the move could attract follow-through buying or a quick profit-taking reversal.
ALTHE.PA stock: Meyka grade and forecast model
Meyka AI rates ALTHE.PA with a score out of 100: Meyka AI rates ALTHE.PA with a score 66.93 / 100, Grade B — HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a 1-year target €0.90, a 3-year target €1.56 and a 5-year target €2.20. Compared with today’s €0.87, the 1-year model implies +3.55% upside. Forecasts are model-based projections and not guarantees.
ALTHE.PA stock: Risks, catalysts and strategy
Key risks include continued negative earnings, thin revenue scale and negative book value per share. Catalysts to watch: regulatory approvals for SONOVEIN or ECHOPULSE sales growth and positive clinical updates. For traders, the high volume move creates a short-term trading opportunity; for investors, focus on cash runway, partnerships and upcoming earnings announcement scheduled 27 Apr 2026. Use strict position sizing given high volatility and low market cap.
Final Thoughts
ALTHE.PA stock’s 22.75% jump on 27 Jan 2026 reflects a raw technical reaction to heavy volume and renewed peer-screening interest rather than a single company statement. Financials show continued losses (EPS -0.11) and stretched valuation metrics (price/sales 28.17, negative price/book). Technically, support near €0.62 and resistance at €0.93 give a clear short-term trading map. Meyka AI’s forecast model projects a 1-year target of €0.90, implying +3.55% upside from the €0.87 close; a 3-year scenario reaches €1.56 (implied +78.16%). Remember forecasts are model-based projections and not guarantees. Given the €34,429,136.00 market cap, tight liquidity and operating cash flow pressures, we view ALTHE.PA as a higher-risk holding best suited to disciplined traders or patients who monitor clinical and commercial milestones. This piece uses Meyka AI as an AI-powered market analysis platform to frame data-driven scenarios and risk points.
FAQs
What drove the ALTHE.PA stock spike on 27 Jan 2026?
The rise followed heavy trading and renewed sector screening on investing platforms. No single Theraclion release explained the move; increased attention to peers and volume-driven momentum appear to be the main drivers.
What is Meyka AI’s short-term forecast for ALTHE.PA stock?
Meyka AI’s forecast model projects a 1-year target of €0.90, implying about +3.55% upside from the €0.87 close. These are model projections and not guarantees.
Is ALTHE.PA stock a buy or hold given current metrics?
Meyka AI assigns ALTHE.PA a 66.93/100 (Grade B — HOLD). The company shows liquidity but negative earnings. This suggests caution; monitor clinical updates and cash flow before adding exposure.
What are the main risks for ALTHE.PA stock investors?
Primary risks are continued operating losses, negative book value per share, low market cap and thin trading liquidity. Regulatory or sales setbacks for Theraclion’s devices would also pressure the price.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
